Kim JH et al. – This observational study shows that the use of SES is superior to paclitaxel–eluting stents (PES) or zotarolimus–eluting stent (ZES) for the target–lesion failure (TLF) in the overall and matched analysis.Methods
- Total 2769 patient who underwent successful percutaneous coronary intervention (PCI) with the three drug eluting stents (DES) between April 2006 and July 2008, were analyzed retrospectively.
- 1152 patients were treated with SES, 810 with PES, and 807 with ZES.
- The primary analysis endpoint was cumulative rate of target–lesion failure (TLF) at 24 months, defined as the composite of cardiac death, target–vessel related myocardial infarction (MI), and target–lesion revascularization (TLR).
- At 24 months, the incidence of TLF was significantly lower in the SES group compared with the ZES (7.6% vs. 11.3%, HR=0.66, CI 0.49 to 0.88, P=0.005) or the PES group (7.6% vs. 10.2%, HR=0.74, CI 0.55 to 0.99, P=0.048), while similar between the PES and the ZES groups (HR=0.89, CI 0.66 to 1.20, P=0.443).
- The difference was mostly driven by higher rate of TLR in the ZES and PES groups compared with the SES group, mostly within the first year post–PCI.
- However, the rate of hard endpoints (cardiac death or nonfatal MI) was similar among the three groups.
- These results were reproduced in the propensity score–matched cohort.